Literature DB >> 26951511

Antigen-specific T cell response from dendritic cell vaccination using side population cell-associated antigens targets hepatocellular carcinoma.

Xiao Li1, Zhuochao Zhang1, Guoying Lin2, Yuanxing Gao2, Zhen Yan2, Heliang Yin2, Bingyi Sun2, Fangyuan Wang2, Haijun Zhang2, Hong Chen3, Dayong Cao4.   

Abstract

Dendritic cell (DC) vaccination targeting cancer stem cells is an effective way to suppress tumor progression and reduce the metastasis and recurrence. In the present study, we explored the suitability of side population (SP) cells as source of antigens for DC vaccination against hepatocellular carcinoma (HCC) in a mouse model. In this study, we identified the "stem-like" characteristics of SP cells in the MHCC97 and Hepa 1-6 HCC cell lines. We found that SP cells express high levels of tumor-associated antigens and MHC class I molecules. Although loading with cell lysates did not change the characteristics of DCs, SP cell lysate-pulsed DCs induced antigen-specific T cell responses, including T cell proliferation and increased IFN-γ production by stimulated CD8(+) T cells. We investigated the cytotoxicity of T cells stimulated by SP cell lysate-pulsed DCs in nude mice co-injected with MHCC97 cells. To mimic the in vivo environment, we also confirmed the result in mouse HCC cell line Hepa 1-6 induced tumor-bearing C57/BL6 immune competent mice, and we demonstrated that vaccination with DCs loaded with Hepa 1-6 SP cell lysates could induce a T cell response in vivo and suppress the tumor growth. Our results may have applications for anti-HCC immunotherapy by targeting the cancer stem cells and may provide new insight for cancer vaccines.

Entities:  

Keywords:  Cancer stem cells; Cytotoxic T lymphocytes; Dendritic cells; Hepatocellular carcinoma; Side population cells

Mesh:

Substances:

Year:  2016        PMID: 26951511     DOI: 10.1007/s13277-016-4935-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  36 in total

Review 1.  Novel insights into the molecular mechanisms of HLA class I abnormalities.

Authors:  Barbara Seliger
Journal:  Cancer Immunol Immunother       Date:  2011-11-27       Impact factor: 6.968

2.  Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties.

Authors:  Tetsuhiro Chiba; Kaoru Kita; Yun-Wen Zheng; Osamu Yokosuka; Hiromitsu Saisho; Atsushi Iwama; Hiromitsu Nakauchi; Hideki Taniguchi
Journal:  Hepatology       Date:  2006-07       Impact factor: 17.425

Review 3.  Immunotherapy with dendritic cells loaded with glioblastoma stem cells: from preclinical to clinical studies.

Authors:  Gaetano Finocchiaro; Serena Pellegatta
Journal:  Cancer Immunol Immunother       Date:  2015-09-16       Impact factor: 6.968

4.  Mouse glioma immunotherapy mediated by A2B5+ GL261 cell lysate-pulsed dendritic cells.

Authors:  Ming Xu; Yu Yao; Wei Hua; Zhebao Wu; Ping Zhong; Ying Mao; Liangfu Zhou; Feifei Luo; Yiwei Chu
Journal:  J Neurooncol       Date:  2014-01-08       Impact factor: 4.130

5.  Comparison of cytotoxic T lymphocyte responses against pancreatic cancer induced by dendritic cells transfected with total tumor RNA and fusion hybrided with tumor cell.

Authors:  Jiang Chen; Xiao-Zhong Guo; Hong-Yu Li; Di Wang; Xiao-Dong Shao
Journal:  Exp Biol Med (Maywood)       Date:  2015-03-02

6.  Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer.

Authors:  Masanori Kobayashi; Tomoyo Sakabe; Hirofumi Abe; Mitsugu Tanii; Hidenori Takahashi; Asako Chiba; Eri Yanagida; Yuta Shibamoto; Masahiro Ogasawara; Shun-ichi Tsujitani; Shigeo Koido; Kazuhiro Nagai; Shigetaka Shimodaira; Masato Okamoto; Yoshikazu Yonemitsu; Noboru Suzuki; Masaki Nagaya
Journal:  J Gastrointest Surg       Date:  2013-07-20       Impact factor: 3.452

7.  Identification of a novel HLA-A2-restricted mutated Survivin epitope and induction of specific anti-HCC CTLs that could effectively cross-recognize wild-type Survivin antigen.

Authors:  Han Shen; Hong-Wei Shao; Xiao-Hua Chen; Feng-Lin Wu; Hui Wang; Zhao-Liang Huang; Juan Shen; Teng Wang; Wen-Feng Zhang; Shu-Lin Huang
Journal:  Cancer Immunol Immunother       Date:  2012-08-29       Impact factor: 6.968

Review 8.  Dendritic-cell-based therapeutic cancer vaccines.

Authors:  Karolina Palucka; Jacques Banchereau
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

9.  Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma.

Authors:  Da-Yong Cao; Jing-Yue Yang; Shu-Qiang Yue; Kai-Shan Tao; Zhen-Shun Song; De-Sheng Wang; Yan-Ling Yang; Ke-Feng Dou
Journal:  Cell Immunol       Date:  2009-05-27       Impact factor: 4.868

10.  Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients.

Authors:  D Reyes; L Salazar; E Espinoza; C Pereda; E Castellón; R Valdevenito; C Huidobro; M Inés Becker; A Lladser; M N López; F Salazar-Onfray
Journal:  Br J Cancer       Date:  2013-08-29       Impact factor: 7.640

View more
  3 in total

Review 1.  Dendritic cells based immunotherapy.

Authors:  Na Shang; Matteo Figini; Junjie Shangguan; Bin Wang; Chong Sun; Liang Pan; Quanhong Ma; Zhuoli Zhang
Journal:  Am J Cancer Res       Date:  2017-10-01       Impact factor: 6.166

Review 2.  Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma.

Authors:  Xiaomeng Dai; Yixuan Guo; Yan Hu; Xuanwen Bao; Xudong Zhu; Qihan Fu; Hangyu Zhang; Zhou Tong; Lulu Liu; Yi Zheng; Peng Zhao; Weijia Fang
Journal:  Theranostics       Date:  2021-01-19       Impact factor: 11.556

3.  Mesenchymal Stromal Stem Cell-Derived Microvesicles Enhance Tumor Lysate Pulsed Dendritic Cell Stimulatedzzm321990Autologous T lymphocyte Cytotoxicity

Authors:  Nasim Rahmani Kukia; Reza Alipanah-Moghadam; Nowruz Delirezh; Mohammad Mazani
Journal:  Asian Pac J Cancer Prev       Date:  2018-07-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.